期刊文献+

HMGB1基因在人脑胶质瘤中的表达及临床意义Meta分析 被引量:6

Expression of HMGB1 gene and its clinical significance in human glioma: a Meta-analysis
下载PDF
导出
摘要 目的评估高迁移率族蛋白B1(HMGB1)在人脑胶质瘤组织中的表达及临床意义。方法通过检索Pub Med、Embase、Ovid、中国期刊网全文数据库(CNKI)和万方等数据库,获取关于HMGB1和胶质瘤关系的文献,根据纳入与排除标准将最后筛选出的文献使用Revman 5.3软件进行Meta分析。结果最终纳入7篇符合标准文献,共576例患者,Meta分析结果显示:胶质瘤和对照组HMGB1表达的差异采用检测方法免疫组织化学法(IHC)[优势比(OR)=26.53;95%可信区间(CI)=13.70~51.35;P<0.01]和实时荧光定量聚合酶链式反应(RT-PCR)[均数差(MD)=16.55;95%CI=11.21~21.90;P<0.01]、HMGB1表达与胶质瘤病理分级关系的表达差异(OR=0.53;95%CI=0.31~0.90;P=0.02)均有统计学意义,而HMGB1表达与胶质瘤是否伴有癫痫(OR=5.32;95%CI=0.10~293.11;P=0.41)差异无统计学意义。结论 HMGB1表达相比对照组胶质瘤中的显著升高,且与胶质瘤病理分级相关,提示HMGB1有望应用作为胶质瘤病理分级诊断及判断预后的重要参考依据,伴有癫痫的胶质瘤组织与不伴有癫痫相比HMGB1表达无差异,没有诊断价值。 Objective The expression of high mobility group box-1 (HMGB1) and its clinical significance in human glioma were evaluated. Methods The literatures on HMGB1 and glioma were obtained by retrieving databases such as Pubmed, Embase, Ovid, Chinese National Knowledge Infrastructure (CNKI). Meta-analysis was conducted by Revman 5.3 software. Results Eventually 7 case-control studies were enrolled. HMGB1 expression in glioma group versus control group detected by immunohistochemistry (IHC) [ Odds ratio (OR) = 26.53 ; 95 % confidence intervals ( C I) = 13.70 - 51.35 ; P 〈 0.01 ] and real-time fluorescence quantitative polymerase chain reaction (RT-PCR) [ mean difference(MD) = 16.55 ; 95% CI = 11.21 - 21.90 ; P 〈 0.01 ], and HMGB1 expression in glioma pathological grade ( OR = 0.53 ; 95% CI =0.31 -0.90; P =0.02) were all statistically significant. HMGB1 expression in glioma with epilepsy versus not with epilepsy was not significantly different ( OR = 5.32 ; 95% CI = 0.10 -293.11 ; P = 0.41 ). Conclusion HMGB1 expression is significantly higher than that in the control group, and it is related to the pathological grade of glioma, suggesting that HMGB1 is expected to be used as an important reference for the diagnosis and prognosis of glioma. There is no difference in the expression of HMGB1 between glioma with epilepsy and not with epilepsy.
出处 《中华神经外科疾病研究杂志》 CAS 2018年第1期23-26,共4页 Chinese Journal of Neurosurgical Disease Research
基金 国家自然科学基金资助项目(30471774) 陕西省自然科学基金资助项目(2003C1-16)
关键词 高迁移率族蛋白B1 胶质瘤 META分析 High mobility group box-1 Glioma Meta-analysis
  • 相关文献

参考文献5

二级参考文献104

  • 1Crispe IN. The Liver as a lymphoid organ. Annu Rev Immunol, 2009,27 : 147-163.
  • 2Rabinovich GA, Gabrilovieh D, Sotomayor EM. lmmunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol, 2007,25:267-296.
  • 3Drake CG, Jaffee E, Pardoll DM. Mechanisms of immune evasion by tumors. Adv Immuno1,2006 ,90 :51-81.
  • 4Maeda S, Hikiba Y, Shibata W, et al. Essential roles of high- mobility group box 1 in the development of murine colitis and colitis-associated cancer. Biochem Bioph Res Co,2007,360 : 394- 400.
  • 5Liang X, Chavez AR, Schapiro NE, et al. Ethyl pyruvate administration inhibits hepatic tumor growth. J Leukocyte Biol, 2009,86:599-807.
  • 6Lim SC, Choi JE, Kim CH, et al. Ethyl pyruvate induces necrosis- to-apoptosis switch and inhibits high mobility group box protein 1 release in A549 lung adenocarcinoma cells. Int J Mol Med,2007, 20 : 187-192.
  • 7Tang D, Kang R, Xiao W, et aL Quercetin prevents LPS-induced high-mobility group box 1 release and proinflammatory function. Am J Respir Cell Mol Bio1,2009 ,41:6514560.
  • 8Hanford LE, Enghild JJ, Valnickova Z, et al. Purification and characterization of mouse soluble receptor for advanced glycation end products (sRAGE), J Biol Chem,200d- ,279:50019-50024.
  • 9Dong Xda E,ho N,Lotze MT,et al. High mobility group box I ( HMGB1 ) release from tumor cells after treatment:implications for development of targeted chemoimmunotherapy. J Immunother, 2007,30:596-606.
  • 10Dudley ME, Rosenberg SA. Adoptive-cell-transfer therapy for the treatment of patients with cancer. Nat Rev Cancer, 2003,3 : 666- 675.

共引文献29

同被引文献35

引证文献6

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部